Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Tectonic Therapeutic, Inc.(TECX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TECX
09/25/2026: TECX (1-star) is currently NOT-A-BUY. Pass it for now.
Tectonic Therapeutic is a clinical-stage biotechnology company developing GPCR-targeted therapies via its proprietary GEODe platform. The firm's key strength lies in its specialized approach to difficult drug targets and its focus on significant medical needs, such as PH-HFpEF. Its primary investment story centers on the potential for its clinical candidates to reach commercialization, thereby validating its technology. However, it faces substantial risks, including a lack of revenue, high cash burn, and the inherent uncertainty of clinical development. The stock is best suited for growth-oriented investors with high risk tolerance who are willing to monitor binary clinical milestones rather than near-term income.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth opportunity dependent on clinical success rather than established revenue streams. |
| Momentum investor | Weak fit | Momentum is often erratic in early-stage biotech; suitability is conditional on positive clinical data readouts. |
| Value investor | Weak fit | The company lacks earnings, making traditional value metrics inapplicable for assessment. |
| Dividend investor | Weak fit | Tectonic is a pre-revenue biotechnology company that does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and binary nature of clinical outcomes make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are prone to sharp price swings based on clinical news and market sentiment. |
| Valuation risk | High | Valuation is speculative and highly sensitive to management's ability to execute clinical milestones. |
| Competition risk (Biopharma incumbents) | High | Larger, well-capitalized competitors can outspend and outmaneuver smaller firms in clinical development. |
| Business quality | Medium | The company has a focused platform, but commercial execution remains unproven. |
| Dividend income | Low / none | There is no dividend income as the company is entirely focused on development. |
| Execution risk | High | The entire investment thesis hinges on the successful, timely completion of complex clinical trials. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 42.82% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 462.73M USD | Price to earnings Ratio - | 1Y Target Price 76.62 |
Price to earnings Ratio - | 1Y Target Price 76.62 | ||
Volume (30-day avg) 207.0K shares | Beta 0.22 | 52 Weeks Range 14.60 - 39.53 | Updated Date 09/27/2026 |
52 Weeks Range 14.60 - 39.53 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.57 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical and preclinical research of GPCR-targeted therapies like TX001. | The company does not make money yet; it spends cash to develop drugs hoping for future regulatory approval. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 265.48M | Price to Sales(TTM) - |
Enterprise Value 265.48M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 19.55M | Shares Floating 11.91M |
Shares Outstanding 19.55M | Shares Floating 11.91M | ||
Percent Insiders 37.85 | Percent Institutions 71.75 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Tectonic Therapeutic, Inc.
Exchange NASDAQ | Headquarters Watertown, MA, United States | ||
IPO Launch date 2018-06-21 | President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://tectonictx.com |
Full time employees 60 | Website https://tectonictx.com | ||
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.